Table 2. Median number of lines of treatments that patients had received.

Patients	Treatments patients received	Median lines (range)
KRAS mutant patients	Had used oxaliplatin-based regimens (N = 131)	2 (1–5)
	Never used oxaliplatin-based regimens (N = 38)	1 (1–4)
	Had used irinotecan-based regimens (N = 137)	2 (1–6)
	Never used irinotecan-based regimens (N = 32)	1 (1–3)
	Had used bavacizumab-based regimens (N = 103)	2 (1–6)
	Never used bevacizumab-based regimens (N = 66)	2 (1–5)
	Had used cetuximab-based regimens (N = 43)	3 (1–6)
	Never used cetuximab-based regimens (N = 126)	2 (1–5)
KRAS wild-type patients	Had used oxaliplatin-based regimens (N = 185)	3 (1–6)
	Never used oxaliplatin-based regimens (N = 40)	1 (1–3)
	Had used irinotecan-based regimens (N = 181)	3 (1–6)
	Never used irinotecan-based regimens (N = 44)	2 (1–3)
	Had used bevacizumab-based regimens (N = 100)	3 (1–6)
	Never used bevacizumab-based regimens (N = 125)	2 (1–5)
	Had used cetuximab-based regimens (N = 134)	3 (1–6)
	Never used cetuximab-based regimens (N = 91)	2 (1–5)